25 completed, 13 recruiting, 12 not yet recruiting, 5 active not recruiting. 19 Phase 3, 16 Phase 2, 12 Phase 4, 4 Phase 1.
Follow rimegepant sulfate: new trials by email Literature Review of rimegepant sulfate trials Research Report on rimegepant sulfate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea Rimegepant sulfate - Migraine With or Without Aura | Not yet recruiting | Pfizer | 3000 | 2027-03-01 | 2026-09-25 | |
| A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study Rimegepant, Flunarizine - Vestibular Migraine | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 400 | 2026-12-01 | 2026-08-07 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant, Tislelizumab, Nab-paclitaxel - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 220 | 2026-10-01 | 2026-09-10 |
| Rimegepant For Endometriosis Pain Rimegepant 75 MG, Placebo - Endometriosis, Endometriosis-related Pain | Phase 2 | Not yet recruiting | Mayo Clinic | 132 | 2026-09-30 | 2026-08-31 |
| Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine Rimegepant 75 MG - Migraine | Not yet recruiting | Nordlandssykehuset HF | 60 | 2026-09-17 | 2026-09-21 | |
| A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine Rimegepant, Placebo - Preventive Treatment of Migraine | Phase 3 | Recruiting | Pfizer | 400 | 2026-08-26 | 2026-10-14 |
| A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India Rimegepant 75 mg ODT - Acute Treatment of Migraine | Phase 4 | Recruiting | Pfizer | 60 | 2026-07-24 | 2026-10-15 |
| Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy Rimegepant, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 12 | 2026-07-06 | 2026-09-22 |
| A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department Rimegepant, Zavegepant - Migraine, Migraine Disease | Phase 1 | Not yet recruiting | University of South Florida | 100 | 2026-07-01 | 2026-06-25 |
| A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine Rimegepant - Acute Treatment of Migraine | Phase 4 | Recruiting | Pfizer | 400 | 2026-05-28 | 2026-10-14 |
| Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL Rimegepant, Glofitamab, Obinutuzumab - Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 100 | 2026-05-01 | 2026-05-29 |
| Efficacy and Safety of Rimegepant for Acute Dizziness Rimegepant 75mg Orally Disintegrating Tablets (ODT), Betahistine Mesylate tablet - Dizziness | Phase 2 / Phase 3 | Not yet recruiting | Shi Tianming | 370 | 2026-03-20 | 2026-02-27 |
| Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma Rimegepant plus Nab-Paclitaxel and Gemcitabine - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Xiuchao Wang | 30 | 2026-03-01 | 2026-03-16 |
| Consistency of Response With Rimegepant in Acute Treatment of Migraine Rimegepant for acute migraine treatment - Migraine | Active not recruiting | Pfizer | 250 | 2025-11-15 | 2026-09-21 | |
| Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US Rimegepant 75 MG - Migraine, Trigger Induced Migraine | Phase 4 | Recruiting | Medstar Health Research Institute | 60 | 2025-09-09 | 2025-12-24 |
| Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients Rimegepant, PD-1 - Colon Cancer | Phase 2 | Not yet recruiting | Fudan University | 20 | 2025-07-01 | 2025-05-31 |
| Acute Migraine Treatment in the ED With Gepants Rimegepant, Zavegepant - Migraine Headaches | Phase 4 | Terminated | Icahn School of Medicine at Mount Sinai | 9 | 2025-06-05 | 2026-04-29 |
| The R-E-V-I-V-A-L Study Rimegepant, Placebo - Vestibular Migraine | Phase 2 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 240 | 2025-06-01 | 2025-06-25 |
| A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment Rimegepant, Placebo - Vestibular Migraine, Adults 18 Years and Older (no Other Exclusion Criteria) | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 240 | 2025-06-01 | 2025-05-14 |
| A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Rimegepant, Placebo Comparator, Standard of Care - Menstrual Migraine | Phase 3 | Recruiting | Pfizer | 723 | 2025-03-11 | 2026-07-09 |
Showing 20 of 61. Sign in to see all of them.
Migraine Disorders (39) · Headache (7) · Hyperacusis (5) · Pain (5) · Photophobia (5) · Migraine with Aura (4) · Migraine without Aura (4) · Nausea (4) · Headache Disorders, Secondary (2) · Agnosia (1) · Cluster Headache (1) · Colonic Neoplasms (1) · Cystitis, Interstitial (1) · Diabetes Insipidus (1) · Dizziness (1)
Pfizer (33) · Mayo Clinic (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Antonios Likourezos (2) · University of Florence (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Danish Headache Center (1) · Eli Lilly and Company (1) · Fudan University (1) · Icahn School of Medicine at Mount Sinai (1) · Medstar Health Research Institute (1) · Nordlandssykehuset HF (1) · Ruijin Hospital (1) · Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine (1)
United States (35) · China (15) · Italy (8) · Poland (8) · Spain (8) · Canada (7) · Japan (6) · United Kingdom (6) · Denmark (4) · Germany (4) · Mexico (4) · Sweden (4) · Austria (3) · Finland (3) · France (3)
Carrie Robertson, MD (1) · Howard B Goldman, MD (1) · Jessica Ailani, MD (1) · Jonathan Schimmel (1) · Jun Liu (1) · Karl B. Alstadhaug, MD, PhD (1) · Leily Naraghi, MD (1) · Messoud Ashina, Prof. (1) · Michael Camilleri (1) · Richard D Granstein, MD (1) · Sergey Motov, MD (1) · Yohannes Woldeamanuel, MD (1)
PMID 31311674, PMID 36739511, PMID 37210098, PMID 41652666, PMID 42839212, PMID 11222783, PMID 26224714, PMID 30020261, PMID 36946234, PMID 37042545, PMID 37073858, PMID 39344988, PMID 41235617, PMID 23965396, PMID 31291516, PMID 31932515, PMID 33338437, PMID 34455556, PMID 35038983, PMID 36125279, PMID 36417057, PMID 38174577, PMID 38627638, PMID 38659334, PMID 38764606, PMID 38985436, PMID 39070853, PMID 39333875, PMID 39520634, PMID 39762740, PMID 40542538, PMID 40583813, PMID 40586377, PMID 40629887, PMID 41066271, PMID 41204073, PMID 41255093, PMID 41255098, PMID 41366286, PMID 41430107, PMID 41637861, PMID 41761058, PMID 41779821, PMID 41930741, PMID 42047365, PMID 42802816, PMID 42816745, PMID 42828704
2023 (1)